Identification of neoplasms expressing programmed cell death 1-ligand 1 (clone SP142)
Immunohistochemistry (IHC)
PDL1
SP142
ISPDL1SP142IHC
GPPDL1SP142
Special
For information on selection of programmed cell death 1-ligand 1 (PD-L1) testing, see https://news.mayocliniclabs.com/pd-l1-by-immunohistochemistry/
Attach the green pathology address label included in the kit to the outside of the transport container.
A pathology/diagnostic report and a brief history, including primary site of neoplasm, are required.
Supplies: Pathology Packaging Kit (T554)
Specimen Type: Formalin-fixed, paraffin-embedded tissue block; or 3 unstained glass, "positively charged" slides with 4-microns formalin-fixed, paraffin-embedded tissue
Additional Information: One slide will be stained with hematoxylin and eosin and returned.
If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:
Immunohistochemical (IHC)/In Situ Hybridization (ISH) Stains Request (T763)
Oncology Test Request (T729)
Wet/frozen tissue Cytology smears Nonformalin fixed tissue Nonparaffin embedded tissue Noncharged slides ProbeOn slides | Reject |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Special | Ambient (preferred) | ||
Refrigerated |
Identification of neoplasms expressing programmed cell death 1-ligand 1 (clone SP142)
Programmed cell death 1-ligand 1 (PD-L1), also known as B7 homolog 1 (B7-H1) or CD274, is a transmembrane protein involved in the regulation of cell-mediated immune responses through interaction with the receptor programmed death protein-1. PD-L1 has been identified as both a prognostic and theranostic marker in a variety of neoplasms. Overexpression of PD-L1 has been observed in carcinomas of the urinary bladder, lung, thymus, colon, pancreas, ovary, breast, kidney, and in melanoma and glioblastoma.
The results of the test will be reported in form of scores. The scoring system is based on type and origin of tumor. If additional interpretation or analysis is needed, order PATHC / Pathology Consultation along with this test.
Preclinical studies suggest that positive programmed cell death 1-ligand 1 (PD-L1) immunohistochemistry in tumor cells may predict tumor response to therapy with immune checkpoint inhibitors. This result should not be used as the sole factor in determining treatment, as other factors (eg, tumor mutation burden and microsatellite instability) have also been studied as predictive markers.
This test has been validated for nondecalcified paraffin-embedded tissue specimens fixed in 10% neutral-buffered formalin. This assay has not been validated on tissues subjected to the decalcification process or use of alternative fixatives for bone and bone marrow specimens or cell blocks.
Age of a cut paraffin section can affect immunoreactivity. Stability thresholds vary widely among published literature and are antigen dependent. Best practice is for paraffin sections to be cut within 6 weeks.
1. Rimm DL, Han G, Taube JM, et al: A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assay for PD-L1 expression in non-small cell lung cancer. JAMA Oncol. 2017 Aug 1;3(8):1051-1058. doi: 10.1001/jamaoncol.2017.0013
2. Gaule P, Smithy JW, Toki M, et al: A quantitative comparison of antibodies to programmed cell death 1 Ligand 1. JAMA Oncol. 2017 Feb;3(2):256-259. doi: 10.1001/jamaoncol.2016.3015
3. Sunshine JC, Nguyen P, Kaunitz G, et al: PD-L1 expression in melanoma: A quantitative immunohistochemical antibody comparison. Clin Can Res. 2017 Aug;23(16):4938-4944. doi: 10.1158/1078-0432.CCR-16-1821
4. D'Incecco A, Andreozzi M, Ludovini V, et al: PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer. 2015 Jan;112(1):95-102. doi: 10.1038/bjc.2014.555
5. Mansfield AS, Roden AC, Peikert T, et al: B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol. 2014 Jul;9(7):1036-1040. doi: 10.1097/JTO.0000000000000177
Immunohistochemistry on sections of paraffin-embedded tissue using Ventana PD-L1 clone SP142.(Unpublished Mayo method)
Monday through Friday
This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.
88360
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
SP142 | PD-L1 (SP142) SemiQuant IHC, Manual | 85149-3 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
603770 | Interpretation | 59465-5 |
603771 | Participated in the Interpretation | No LOINC Needed |
603772 | Report electronically signed by | 19139-5 |
603773 | Material Received | 81178-6 |
603774 | Disclaimer | 62364-5 |
603775 | Case Number | 80398-1 |